Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
Dr. John Cush RheumNow
1 week 1 day ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
sheila RHEUMarampa
1 week 1 day ago
Roc-SpA study
Active axSpA dse + inad response to TNFi ➡️switch or cycled
No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi
Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi
Shared decision is key
AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP002 In 20 active #lupus nephritis patients with paired kidney biopsy at baseline & 1 yr, urine proteomics showed histology response correlated with restoration of immune, coagulation and ECM-remodelling pathways. Need to advance this liquid biopsy in clinic @RheumNow https://t.co/KaZSYlA9V1
Aurelie Najm AurelieRheumo
1 week 1 day ago
What if we let RA patients choose ttmt?
BACH RCT choice between Filgo / scTNFi vs. standard randomisation
55% JAKi vs 45% TNFi
Higher ttmt satisfaction 46 vs 33 p=0.012
Less ttmt switches 6 vs 15 p=0.026
Less AE reported
Better drug survival
Shared decision making is key! https://t.co/1YS0y6YUEH
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0236: a look at the revised 2025 ASAS-SPARTAN classification criteria for axSpA from the global CLASSIC cohort. The updated criteria achieved 79.5% sensitivity & 90.4% specificity, with MRI & radiographic sacroiliitis remaining central to classification. #EULAR2026 @RheumNow https://t.co/rVIqyCmB8K
Janet Pope Janetbirdope
1 week 1 day ago
Is there a ‘window
Of opportunity’ for Rx
#GCA w #IL6i
🤞
Obtain a better response
Rx GCA #GC
#TCZ
#Upadacitinib
#MTX
Study tries to answer if effects of #tocilizumab early vs >8wks is diff
N=471, 19% new GCA
Early vs late TCZ no dif
❎No
Not RCT
POS0624 #EULAR2026 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP002 More encouraging news in #Sjogren. A Phase II RCT in N=30 patients with ESSDAI=>5 and/or ESSPRI=>5: Anifrolumab (IFN-IR mAb) improved CRESS response vs PBO (80% vs 30%). Impressive effect size for other endpoints too. Need definitive Phase III RCT @RheumNow https://t.co/W3GbA3gKIs
Jiha Lee JihaRheum
1 week 1 day ago
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068
Dr. John Cush RheumNow
1 week 1 day ago
COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Aurelie Najm AurelieRheumo
1 week 1 day ago
And we are on!
A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos
@RheumNow https://t.co/zTQUFcjXBI
Mrinalini Dey DrMiniDey
1 week 1 day ago
It’s that time of year again! 🎉
Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London!
@bella_mehta
@JihaRheum
@AurelieRheumo
@Janetbirdope
@Nellziade
@RHEUMarampa
@synovialjoints
@Yuz6Yusof https://t.co/WvhpYJJNUk
Aurelie Najm AurelieRheumo
1 week 1 day ago
"the further I look back, the further I can see the future"
Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026
@eular_org @RheumNow https://t.co/ayInzzb9lO
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A
